Jyong Biotech Responds to Share Price and Volume Movement

Rhea-AI Summary

Jyong Biotech (Nasdaq: MENS) noted increased share price fluctuation and trading volume on Nasdaq following the lock-up expiry in December 2025. The company said it is in compliance with SEC continuous disclosure rules and is not aware of any material, unpublished price-sensitive information explaining the activity.

Jyong Biotech confirmed ongoing talks with certain investment funds about potential share purchases, reported completed clinical work for API-1 (four Phase III trials in the United States and Taiwan and one Phase II in Taiwan), holds global multi-country invention patents across the Americas, Asia, and Europe, and has signed LOIs with several international pharmaceutical companies while planning further botanical drug development.

Positive

• Four Phase III trials for API-1 completed in US and Taiwan
• One Phase II trial completed in Taiwan
• Global multi-country patents across Americas, Asia, and Europe
• LOIs signed with several international pharmaceutical companies

Negative

• Share price and trading volume increased after lock-up expiry, raising volatility risk
• Ongoing discussions with investment funds may contribute to near-term trading uncertainty

Key Figures

Phase III trials 4 trials Completed Phase III clinical trials (API-1) in U.S. and Taiwan

Phase II trials 1 trial Completed Phase II clinical trial in Taiwan

Prostate cancer incidence reduction 27.3% Reduction vs placebo in Phase II trial of MCS-8

High-grade cancer reduction 17.1% Reduction in high-grade prostate cancer vs placebo for MCS-8

Trial enrollment >700 subjects High-risk subjects in Phase II MCS-8 trial across 20 hospitals

Trial duration 2 years Treatment duration in Phase II MCS-8 study

Hospitals involved 20 hospitals Sites participating in Phase II MCS-8 trial in Taiwan

Innovation award prize $26,000 Cash prize from 2025 Taipei Biotech Awards

Market Reality Check

$4.22 Last Close

Volume Volume 2,762,670 is 5.99x the 20-day average 461,311, highlighting unusually heavy trading. high

Technical Price $3.33 is trading below the 200-day MA at $35.75, reflecting a longer-term downtrend.

Peers on Argus

While MENS shows a +14.04% move with high volume, key biotech peers like CRSP, PTCT, TGTX, and MRUS show small declines or modest gains, and no peers appeared in the momentum scanner, suggesting stock-specific activity.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 04	Partnership MOU	Positive	-2.1%	Non-binding MOU for Vietnam MCS-2 commercialization exploration.
Nov 24	LOI partnership	Positive	+15.2%	Non-binding LOI with South Korean pharma for MCS-2 in-licensing.
Nov 20	Phase II results	Positive	+12.4%	Positive Phase II primary endpoint analysis for MCS-8 in >700 subjects.
Sep 29	Innovation award	Positive	-16.3%	Innovation Gold Award for BOTRESO with $26,000 cash prize.
Sep 18	Conference appearance	Neutral	-3.6%	CEO speaking at Global Business Forum on drug tech and capital.

Pattern Detected

Recent company-specific news often triggered sharp but mixed price reactions, with positive clinical or partnership updates sometimes met by gains and other times by selloffs.

Recent Company History

Over the last few months, Jyong Biotech announced multiple partnership explorations for its plant-derived candidate MCS-2 in Korea and Vietnam, with one LOI coinciding with a +15.16% move and another MOU seeing a modest -2.09% reaction. A positive Phase II readout for MCS-8 on Nov 20, 2025 aligned with a +12.44% gain. In contrast, a biotech innovation award with a $26,000 prize on Sep 29, 2025 preceded a -16.3% drop, showing mixed responses to seemingly positive milestones.

Market Pulse Summary

This announcement addresses unusual trading after lock-up expiry, stating that operations, research programs, and financial condition remain consistent with recent filings. It emphasizes completed late-stage trials for API-1 and a broader botanical drug pipeline supported by global patents and multiple LOIs. Investors may focus on how these clinical assets progress to regulatory approvals, the conversion of LOIs into binding deals, and any updates to financial disclosures or development timelines in future filings.

Key Terms

lock-up period financial

"following the expiry of the lock-up period this month."

A lock-up period is a fixed time after a stock offering during which company insiders and early investors are legally barred from selling their shares. It matters because when that restriction expires a large block of previously locked-up shares can enter the market at once, potentially lowering the stock price or spiking trading volume—like opening a floodgate—so investors monitor these dates to anticipate price moves and manage risk.

continuous disclosure obligations regulatory

"in compliance with its continuous disclosure obligations under the SEC regulations."

A legal duty for publicly traded companies to quickly share any material information about their business, finances, operations, or risks with the market so all investors have the same facts at the same time. It matters because timely, equal access to key news helps prices reflect true value, reduces the chance of sudden surprises, and protects investors from unfair advantage—like keeping a public scoreboard updated so everyone sees the current score.

SEC regulations regulatory

"its continuous disclosure obligations under the SEC regulations."

SEC regulations are the rules and requirements set by the U.S. Securities and Exchange Commission that govern how companies report financial information, disclose material events, register securities, and prevent fraud in the markets. They matter to investors because these rules create a predictable, transparent playing field—like traffic laws for the marketplace—helping investors assess risks, compare companies reliably, and reduce the chance of being misled or surprised by hidden problems.

Phase III clinical trials medical

"has completed four Phase III clinical trials (API-1) in the United States and Taiwan"

Phase III clinical trials are large, late-stage studies that test whether a drug or medical treatment is safe and effective when used in the general patient population, often comparing it to existing treatments or a placebo. Investors watch Phase III results closely because they are the final major test before regulators decide on approval—like a final road test that determines whether a product can be sold widely and generate meaningful revenue.

Phase II clinical trial medical

"along with one Phase II clinical trial in Taiwan."

A Phase II clinical trial is a mid-stage study in humans that tests whether an experimental drug or treatment actually works and what dose is effective, typically involving dozens to a few hundred patients and often comparing outcomes to a placebo or standard care. For investors, Phase II results are a major inflection point: clear positive data can substantially increase the odds of later regulatory approval and company value, while negative or uncertain results raise development risk and can sharply reduce expectations—like a detailed test drive after basic safety checks.

investigational pipeline medical

"advancing regulatory approvals and its investigational pipeline."

A company's investigational pipeline is the collection of medical treatments, drugs or devices it is actively developing but has not yet won full regulatory approval. Think of it as a product roadmap or menu of future offerings that may bring revenue if trials succeed and regulators sign off. For investors, the pipeline signals future growth potential and risk: promising candidates can boost value, while failures can reduce it.

invention patents technical

"The Company holds global multi-country invention patents, providing market protection"

Invention patents are government-granted rights that give a company exclusive control over a new device, process, composition or method for a limited time, preventing others from making, using, selling, or importing that invention without permission. For investors, patents act like a legal moat—similar to a lock on a unique product—helping protect future sales, enable licensing revenue, justify higher valuations, and signal lower competition risk, while expiration or invalidation can remove that protection.

LOIs financial

"Concurrently, LOIs have been signed with several international pharmaceutical companies."

Lois is the French word for "laws"—formal rules or statutes created by a government or legislative body that set what businesses can and cannot do. Investors care because changes in lois can alter a company's costs, allowed activities, taxes, reporting requirements, or legal risks, much like new traffic rules can change how drivers plan a route and how long trips take.

AI-generated analysis. Not financial advice.

New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”) notes the recent fluctuation in its share price and the increased trading volume of its shares on the Nasdaq Stock Exchange following the expiry of the lock-up period this month. The Company has been in ongoing discussions with certain investment funds that are interested in purchasing the Company’s ordinary shares.

The Company confirms that it is in compliance with its continuous disclosure obligations under the SEC regulations. The Company is not aware of any material, unpublished price-sensitive information or corporate developments that would explain the recent trading activity.

The Company's research and development, operation remain solid and its financial condition and results of operations remain consistent with the information disclosed in its most recent public filings, including but not limited to its Current Report on Form 6-K.

Jyong Biotech cautions its investors that share price movements can be influenced by various factors, including general market conditions, sector-specific news, and general supply and demand dynamics, which are beyond the Company's control.

The Company remains committed to keeping its shareholders informed of all material developments in accordance with applicable laws and regulations.

Jyong Biotech has completed four Phase III clinical trials (API-1) in the United States and Taiwan, along with one Phase II clinical trial in Taiwan. It plans further development of novel botanical drugs, advancing regulatory approvals and its investigational pipeline. The Company holds global multi-country invention patents, providing market protection across the Americas, Asia, and Europe. Concurrently, LOIs have been signed with several international pharmaceutical companies. The Company is committed to expanding its global presence, aiming to deliver world-class botanical new drugs to address significant unmet medical needs and improve global health outcomes.

About Jyong Biotech Ltd.

Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO^®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.

For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com

Investor Relations
WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Phone: +1 628 283 9214

FAQ

Why did MENS shares move on December 19, 2025?

Jyong Biotech reported increased share price fluctuation and trading volume following the lock-up expiry in December 2025.

Has Jyong Biotech (MENS) disclosed any material nonpublic information about the trading activity?

The company said it is not aware of any material, unpublished price-sensitive information explaining the recent trading activity.

What clinical progress did Jyong Biotech report for API-1 (MENS)?

Jyong Biotech completed four Phase III trials for API-1 in the United States and Taiwan and one Phase II trial in Taiwan.

Does MENS hold intellectual property protection for its drugs?

The company holds global multi-country invention patents covering territories in the Americas, Asia, and Europe.

Are there any agreements with partners mentioned for MENS?

Jyong Biotech said it has signed letters of intent (LOIs) with several international pharmaceutical companies.

Is Jyong Biotech complying with SEC disclosure rules (MENS)?

Yes; the company confirmed it is in compliance with its continuous disclosure obligations under SEC regulations.